Polymyxins: older antibiotics for a new threat.
Polymyxin B and colistin have demonstrated reasonable success in infections due to multidrug-resistant A. baumannii and P. aeruginosa. Polymyxins are only recommended for highly selected cases of serious infections caused by gram-negative bacilli resistant to currently available antibiotics to avoid their potential toxicity. Pharmacodynamic studies are still needed to determine appropriate dosage regimens that will optimize effectiveness and minimize toxicity.
Lee
Su Young
SY
Center for Anti-Infective Research and Development, Hartford Hospital, USA.
Kuti
Joseph L
JL
Nicolau
David P
DP
D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D040981:Acinetobacter baumannii / Q000187:drug effects*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D011113:Polymyxins / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013997:Time Factors
D011113:Polymyxins